Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in High-Risk Newly Diagnosed Multiple Myeloma
NCT02217163Phase 2Completed
- Sponsor
- Singapore General Hospital
- Start
- Oct 2014
- Primary completion
- Oct 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Singapore General Hospital. Primary endpoint: Progression Free Survival at 2 years. Started Oct 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02217163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217163.